# PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants

> **NCT01641510** · PHASE3 · COMPLETED · sponsor: **Dong-A University** · enrollment: 70 (actual)

## Conditions studied

- Acute Coronary Syndromes

## Interventions

- **DRUG:** Prasugrel
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT01641510
- **Lead sponsor:** Dong-A University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2018-10
- **Final completion:** 2019-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641510, "PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01641510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*